Vanguard Capital Wealth Advisors Has $426,000 Stock Position in Bristol-Myers Squibb (NYSE:BMY)

Vanguard Capital Wealth Advisors lifted its position in Bristol-Myers Squibb (NYSE:BMY) by 107.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,300 shares of the biopharmaceutical company’s stock after buying an additional 4,300 shares during the quarter. Vanguard Capital Wealth Advisors’ holdings in Bristol-Myers Squibb were worth $426,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. OFI Invest Asset Management acquired a new stake in shares of Bristol-Myers Squibb in the third quarter worth $25,000. Milestone Investment Advisors LLC acquired a new position in Bristol-Myers Squibb during the 3rd quarter valued at $27,000. Blue Bell Private Wealth Management LLC raised its stake in Bristol-Myers Squibb by 61.5% during the 3rd quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 200 shares during the last quarter. Legacy Financial Group LLC acquired a new position in Bristol-Myers Squibb during the 3rd quarter valued at $39,000. Finally, Turtle Creek Wealth Advisors LLC acquired a new position in Bristol-Myers Squibb during the 4th quarter valued at $40,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol-Myers Squibb Stock Down 1.5 %

Shares of NYSE:BMY traded down $0.68 during midday trading on Tuesday, hitting $43.96. The stock had a trading volume of 17,712,926 shares, compared to its average volume of 15,994,846. Bristol-Myers Squibb has a 12 month low of $43.93 and a 12 month high of $69.10. The company has a quick ratio of 0.99, a current ratio of 1.11 and a debt-to-equity ratio of 2.99. The business’s 50-day simple moving average is $50.93 and its 200-day simple moving average is $51.02. The company has a market cap of $89.11 billion, a P/E ratio of -14.38, a PEG ratio of 15.47 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, beating the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The business had revenue of $11.87 billion during the quarter, compared to analysts’ expectations of $11.45 billion. During the same period last year, the business earned $2.05 earnings per share. The firm’s revenue was up 4.7% on a year-over-year basis. On average, sell-side analysts forecast that Bristol-Myers Squibb will post 0.58 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be issued a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 5.46%. The ex-dividend date is Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio is -77.42%.

Analyst Ratings Changes

BMY has been the subject of several research analyst reports. Societe Generale cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. Wells Fargo & Company boosted their price target on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a report on Thursday, April 18th. StockNews.com lowered shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Monday, April 15th. William Blair reissued a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. Finally, Barclays decreased their price objective on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a report on Friday. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $60.00.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.